Jaewoo Kang
Chief Executive Officer AIGEN Sciences
– Published with over 9000 citations
– Leading expert in AI-driven drug discovery.
– Professor of Computer Science at Korea University (since 2006),
previously at North Carolina State University.
– Developed BioBERT, the most-cited biomedical AI language model (>7,000 citations).
– Secured multiple AI drug discovery challenge wins and led collaborations with AstraZeneca
on AI-driven frameworks.
– Ph.D. in Computer Science from the University of Wisconsin-Madison.
Seminars
This workshop will help attendees master two critical enabling technologies, proteomics and AI. Discussions will revolve around how to design and apply proteomics workflows for selectivity profiling and mechanistic clarity, and how to use AI-driven analytics to interpret complex datasets and accelerate degrader design and modeling. By the end of the session, attendees will have practical strategies to improve reliable data generation and analysis and how to use this to inform critical drug design decisions.
Key Takeaways:
- Integrating high-throughput discovery platforms into your workflows to accelerate the discovery and development of molecular glues
- Beyond screening: Accelerating TPD and induced proximity discovery with agentic AI and large language models
- Exploring case studies on how advanced biotechs combine the latest platform technology and AI tools to reduce experimental burden, improve translational predictability, and enable scalable discovery
